US Stock MarketDetailed Quotes
GNFT Genfit
- 4.240
- -0.070-1.62%
Close Nov 21 16:00 ET
211.60MMarket Cap10.93P/E (TTM)
4.240High4.240Low705Volume4.240Open4.310Pre Close3.06KTurnover0.00%Turnover RatioLossP/E (Static)49.91MShares6.42352wk High2.08P/B178.06MFloat Cap3.08052wk Low--Dividend TTM41.99MShs Float26.250Historical High--Div YieldTTM0.00%Amplitude2.894Historical Low4.334Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Genfit Stock Forum
GENFIT will present pre-clinical data as part of its ACLF franchise with the following posters:
VS-01: Effect of VS-01 on Acute-on-Chronic Liver failure-related toxins such as lipopolysaccharide and hydrophobic bile acids in vitro (poster #1603)
SRT-015: Intravenous administration with the ASK1 inhibitor SRT-015 alleviates liver injury and systemic inflammation ...
Capital Markets: $UP Fintech (TIGR.US)$ $Cipher Mining (CIFR.US)$ $CleanSpark (CLSK.US)$
Biotechnology: $Genfit (GNFT.US)$ $Spyre Therapeutics (SYRE.US)$ $Krystal Biotech (KRYS.US)$
Software: $Verb Technology (VERB.US)$ $SurgePays (SURG.US)$ $Uber Technologies (UBER.US)$
Asset Management: $Westwood Holdings (WHG.US)$ $BrightSphere Investment (BSIG.US)$ $Blackrock (BLK.US)$
Specialty Industrial Machinery: $JE Cleantech Holdings Limited (JCSE.US)$ $Taylor Devices (TAYD.US)$ $CSW Industrials (CSWI.US)$
...
The drug will be called Iqirvo, Ipsen said in a statement Monday. (Bloomberg) -- Ipsen SA and partner Genfit SA won US regulators’ clearance for the first new treatment option in eight years for patients with a rare liver disease.
The US Food and Drug Administration approved the medicine, elafibranor, for adults with primary biliary cholangitis, an autoimmune disease in whi...
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : 🤔
⇨ Elafibranor
‣ Primary biliary cholangitis
‣ PDUFA date: 6/10/24
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Kevzara (sarilumab)
‣ Polyarticular juvenile idiopathic arthritis
‣ PDUFA date: 6/10/24
$Bristol-Myers Squibb (BMY.US)$ : 🤔
⇨ Augtyro™ (Repotrectinib)
‣ PDUFA date: 6/15/24 (sNDA)
🗓️ Last week’s PDUFAs:
$GlaxoSmithKline (GSK.US)$ : Approved 6/7 🎉
⇨ Arexvy
‣ Respiratory s...
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis - 10 June 2024 - 12 mins read
Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis
Approval based on positive Phase III ELATIVE trial data Primary biliary cholangitis impacts approximately 100,000 people in the US and is g...
GENFIT Says Iqirvo Is First-ever Drug Developed In-house By Company To Achieve FDA Approval; Expects To Receive Milestone Payments From Ipsen
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Eli Lilly and Co (LLY.US)$ : Donanemab - AdCom meeting 🗓️
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro™ (Repotrectinib)
$Geron (GERN.US)$ : Imetelstat
$Merck & Co (MRK.US)$ : V116
$Amgen (AMGN.US)$ : BLINCYTO (blinatumomab)
$Sarepta Therapeutics (SRPT.US)$ : ELEVIDYS
$Merck & Co (MRK.US)$ : KEYTRUDA ...
June’s investment tactic
I’m thinking about putting more money into biotech stocks through dollar-cost averaging. Biotech stocks can be risky due to factors like drug trials and regulations. I will continue to keep an eye on earnings reports for biotech companies, as they ...
$Bristol-Myers Squibb (BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna (MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals (CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline (GSK.US)$ : Arexvy
$Genfit (GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD (IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals (REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb (BMY.US)$ : Augtyro...
No comment yet